Latest Articles
BioNTech's Cancer Candidate Clears Path for FDA Filing - AD HOC NEWS
BioNTech's Cancer Candidate Clears Path for FDA Filing AD HOC NEWS
Published: April 12, 2026, 12:31 p.m.
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Published: April 12, 2026, 12:58 a.m.
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer Cure Today
Published: April 11, 2026, 9:14 p.m.
Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork
Black Women With Endometrial Cancer Completed Treatment More With Peer Support CancerNetwork
Published: April 11, 2026, 8:04 p.m.
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive
Published: April 11, 2026, 6:14 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative
Published: April 11, 2026, 11:10 a.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
Published: April 11, 2026, 11:01 a.m.
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan
In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan
Published: April 11, 2026, 11 a.m.
Progesterone in MHT for Protection Against Endometrial Cancer - The Vajenda
Progesterone in MHT for Protection Against Endometrial Cancer The Vajenda
Published: April 11, 2026, 9:17 a.m.
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment - BioSpectrum Asia
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment BioSpectrum Asia
Published: April 11, 2026, 7:52 a.m.
Link copied to clipboard!